Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alzheimer's disease.

R Scott Turner1

  • 1Neurology Service, VA Ann Arbor Healthcare System, Michigan 48105, USA.

Seminars in Neurology
|October 19, 2006
PubMed
Summary
This summary is machine-generated.

Alzheimer's disease (AD) involves amyloid plaques, but other factors like tau tangles and inflammation are also crucial. New therapies targeting these aspects may offer disease-modifying benefits for dementia.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intravenous anti-Aβ immunotherapy acutely increases cerebral amyloid angiopathy and vascular damages in APOE4 mice.

bioRxiv : the preprint server for biology·2026
Same author

Developing Topics.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

The financial consequences of undiagnosed memory disorders.

Journal of financial economics·2025
Same author

Voiceprints of cognitive impairment: analyzing digital voice for early detection of Alzheimer's and related dementias.

NPJ dementia·2025
Same author

First-in-human study of neuron regenerative therapy NNI-362 to evaluate the safety, pharmacokinetics, and pharmacodynamics in healthy aged population.

Alzheimer's research & therapy·2025
Same author

Safety, Cognitive, and Behavioral Outcomes in Patients with Dementia with Lewy Bodies Treated with Nilotinib.

Journal of clinical medicine·2025
Same journal

Isolated Cranial Tremors: A Reappraisal.

Seminars in neurology·2026
Same journal

Dystonia and Tremor.

Seminars in neurology·2026
Same journal

Pendular nystagmus and oculopalatal tremor.

Seminars in neurology·2026
Same journal

Sanjay Pandey, MBBS, MD, DNB, DM, FIAN, and Aasef Shaikh, MD, PhD.

Seminars in neurology·2026
Same journal

Tremor.

Seminars in neurology·2026
Same journal

Carotid Disease.

Seminars in neurology·2026
See all related articles

Area of Science:

  • Neuroscience
  • Pathology
  • Gerontology

Background:

  • Alzheimer's disease (AD) is the leading cause of dementia, characterized by amyloid plaque accumulation.
  • The amyloid hypothesis suggests amyloid plaques are central to AD, but other pathologies like tau tangles and neuroinflammation are also implicated.
  • While most AD cases are sporadic, familial forms have illuminated disease mechanisms and therapeutic targets.

Purpose of the Study:

  • To explore the multifactorial nature of Alzheimer's disease pathogenesis beyond the amyloid hypothesis.
  • To discuss the role of downstream pathologies including tau aggregation, neurodegeneration, and neuroinflammation.
  • To evaluate the potential of novel therapeutic strategies in modifying AD progression.

Main Methods:

  • Review of current understanding of AD pathogenesis.

Related Experiment Videos

  • Analysis of the amyloid hypothesis in light of other contributing factors.
  • Examination of preclinical and clinical trial data for novel AD therapies.

    • Main Results:

    • Amyloid deposition is necessary but not sufficient for AD development.
    • Phospho-tau aggregation, synaptic loss, and neuroinflammation are critical components of AD pathogenesis.
    • Existing AD drugs offer symptomatic relief but do not halt disease progression.

    Conclusions:

    • Alzheimer's disease pathogenesis is complex, involving multiple interacting pathologies.
    • Novel disease-modifying therapies targeting various pathways show promise for preventing or arresting dementia.
    • Further research and clinical trials are essential to test the amyloid hypothesis and develop effective treatments.